When COVID-19 researchers started working with us to help them share their reagents, we knew our role in fighting the pandemic could be even more impactful by reaching more scientists. Many members of the scientific community support open sharing. But, one critical part was missing when the COVID-19 plasmids first became available: distribution was limited to academic scientists.
Expanding plasmid sharing during COVID-19
Realizing this limitation, we worked closely with the legal partners and Tech Transfer Offices at universities to make COVID-19 research-related plasmids available more broadly: to scientists in academia and industry. As a result over 90% of Addgene’s COVID-19 resources are now available to scientists working in a for-profit setting.
In light of the need for basic research during the current pandemic, universities are showing an unprecedented amount of support about allowing use of plasmids for research by anyone. As infection rates were increasing in the United States, and many universities and Technology Transfer Offices were, at least, temporarily closing, these groups were willing and able to listen to Addgene’s new approach of working with the industry-based scientific community. Conversations with children playing in the background became a normal occurrence as Addgene and our university partners quickly assessed how to more readily enable research. Often “normal” timelines that could be weeks to months were reduced to days and weeks. As of June 2020, we are happy to have the support of the following organizations to share materials more broadly to accelerate COVID-19 research:
- Sinai Health System
- Universitaetsklinikum Essen
- University of North Carolina at Chapel Hill
- University of Illinois Chicago
- Boston Children's Hospital
- California Institute of Technology
- Johns Hopkins University
- National Institute for Physiological Sciences
- Broad Institute
- Chinese Academy of Medical Sciences
- University of Texas at Austin
- University of California, San Francisco
- University of Pennsylvania
- Stanford University
- University of Iowa
- University of Minnesota
Partnership with Ginkgo Bioworks
While one way to help the scientific community speed research is to offer plasmids created as part of research projects, another way is to systematically offer thousands of constructs for tagged and untagged expression of SARS-CoV-2 proteins in bacteria, yeast, and mammalian cells. We teamed up with Ginkgo Bioworks to quickly bring these plasmids to the scientific community - both academic and industry scientists. This partnership complemented each other's strengths: Ginkgo Bioworks’ infrastructure allowed them to synthesize new plasmids quickly and Addgene’s quality control and archiving system allowed us to handle and distribute such a large deposit. Once the project is complete, Ginkgo will have synthesized approximately 3,000 constructs to support SARS-CoV-2 research.
Beyond COVID-19: Addgene’s plasmid collections available to industry scientists
While we’ve focused on expanding COVID-19 plasmids to industry scientists in the short term, did you know we have other plasmid collections available to industry? Over the past 8 years, several organizations have made their plasmids available beyond academia. For example:
- Plasmids from the Michael J. Fox Foundation are used in Parkinson’s research.
- The extensive resource from the Structural Genomics Consortium enables science to determine the three dimensional structures of proteins.
- The RESOLUTE Consortium collection enables research on solute carriers (SLCs) for medical research
- Recently, the Michael Davidson Fluorescent Protein collection, a ‘One-Stop Shop’ for Fluorescent Proteins, and plasmids from several labs at Florida State University became openly available.
To make plasmid sharing more open for academic and industry scientists, we’ve worked with many scientists, tech transfer offices, research foundations, and funding initiatives such as Fast Grants that support us in our mission.
While rapidly expanding our COVID-19 resources has been our focus for the past months, we’re excited to see our open sharing impact grow beyond COVID-19. But, we can’t do this alone. If you have deposited plasmids at Addgene and would like to make them available to industry, please reach out at email@example.com and we will initiate a conversation with you and your technology transfer office to discuss the possibilities for expanded sharing.
Additional resources on the Addgene blog
- Browse blog posts related to COVID-19
- Learn more about the Ginkgo COVID-19 plasmid collection
- Read about plasmids in the COVID-19 collection
Resources on Addgene.org
- Sign up for Addgene's industry distribution email updates